Data / Form D filings / Erytech Pharma S.A.
Erytech Pharma S.A.: Form D filings
Erytech Pharma S.A., a biotechnology company in Lyon, France, filed 3 Form D notices with the SEC between 2014 and 2015. The latest, on December 22, 2015, reports $4 million sold of a $4 million offering to 7 investors.
Find out what Erytech Pharma S.A. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 60 AVENUE ROCKEFELLER, Lyon, France, 69008
- Phone
- 011-33-4-78-74-44-38
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- France
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1624422
The full lists. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Form D filings: 44,302 rows, $523.02, or the new rows each week for $92.05 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Dec 22, 2015 | New notice | $3,954,924 | $3,954,924 | $0 | 7 | Dec 7, 2015 | sec.gov |
| Nov 10, 2014 | Amendment | Indefinite | $37,232,686 | Indefinite | 33 | Oct 24, 2014 | sec.gov |
| Nov 7, 2014 | New notice | Indefinite | $37,232,686 | Indefinite | 33 | Oct 24, 2014 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| GIL BEYEN | Executive Officer, Director | |
| MARTINE GEORGE | Director | |
| SVEN ANDREASSON | Director | |
| HILDE WINDELS | Director | |
| YANN GODFRIN | Executive Officer, Director | |
| ERIC SOYER | Executive Officer | |
| PHILIPPE ARCHINARD | Director | |
| LUC DOCHEZ | Director | |
| JEROME BAILLY | Executive Officer |
Every Form D from the week of Dec 21, 2015 · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Erytech Pharma S.A. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.